Government sets Thursday deadline for doctors' return
Woman dies after bungee jumping in mall
Over 150 elementary schools have no 1st graders: ministry
[KH explains] Why Korea has been so quick to adopt ‘global minimum tax’
[From the Scene] 12 hours to get ER treatment -- it could get worse
Korea to lift land use restrictions near military bases
Mass walkout by trainee doctors nears deadline as health services crippled
Broadcaster warned after omitting honorific for first lady
Teachers and native English instructors now required to undergo drug testing
Russia sending North Korea food in return for arms: Seoul defense chief
Korean VC firms invest US$16m in UK biotech startupBy 박한나
Published : Oct. 14, 2016 - 17:36
Korea Investment Partners will invest US$6 million while three others including NHN Investment will commit a total of US$10 million into the company developing personalized medicine for cancer patients.
The move marks the first time that Korean venture capital firms are funding a British biotech startup.
As valuations of local biopharma companies have been growing at a rapid clip since last year, domestic investors are turning their eyes to foreign firms, especially those in the UK to benefits from the weak pound that has plunged after the Brexit vote.
Celleron Therapeutics, founded by professors at the University of Oxford, is expected to use the funds for phase 2 clinical trials of its personalized cancer treatment CXD101.
The phase 1 clinical trials showed that it has favorable safety and tolerability in the patients with advanced treatment-resistant aggressive disease, according to the firm.
If it completes the phase 2 clinical trials, a Korean pharmaceutical company which also invested in Celleron Therapeutics plans to enter into an exclusive partnership to commercialize the drug in East Asia.
By Park Han-na (firstname.lastname@example.org)
Deadline looms over trainee doctors’ walkout
S. Korea, US vow stern measures on NK-Russia arms deal
Legality issues linger as nurses fill treatment void Tuesday